CTLA-4 antibody and aromatase inhibitor combination of treatment for breast cancer

An aromatase inhibitor, -CTLA4 technology, applied in the field of cancer immunotherapy, can solve the problems of patients with multiple diseases without radical therapy and palliative treatment

Inactive Publication Date: 2007-10-10
PFIZER PROD INC
View PDF100 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is still no curative cure for patients with multifocal disease, and treatment is largely palliative

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CTLA-4 antibody and aromatase inhibitor combination of treatment for breast cancer
  • CTLA-4 antibody and aromatase inhibitor combination of treatment for breast cancer
  • CTLA-4 antibody and aromatase inhibitor combination of treatment for breast cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0230] The formulations of the pharmaceutical compositions described herein can be prepared by methods known or later developed in the art of pharmacy. In general, such methods of preparation comprise the steps of incorporating the active ingredient into the carrier or one or more other accessory ingredients, and then, if necessary or desired, shaping or packaging the product into desired single or multi-dose units.

[0231] The pharmaceutical compositions useful in the methods of the invention may be prepared, packaged, or administered in dosage forms suitable for oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, ophthalmic, or other routes of administration. Sale. Other contemplated formulations include contemplated nanoparticle, liposomal formulations, resealed red blood cells containing active ingredients, and immunological formulations.

[0232] The pharmaceutical compositions of the invention may be prepared, packaged or sold as a single unit do...

Embodiment

[0282] Anti-CTLA4 antibody combined with exemestane in postmenopausal patients with metastatic or locally advanced breast cancer

[0283] Intravenous infusion of anti-CTLA4 antibody (100ml / hr) was administered to patients with metastatic or locally advanced breast cancer, as described here, who had at least one lesion capable of accurate two-dimensional measurement and conventional CT scan Its size is ≥2cm×1cm, or its size is ≥1cm×1cm by spiral CT scan. Administer prophylactic antiemetics and antidiarrheals as appropriate.

[0284] The treatment was repeated after 28 days. Successive cohorts received escalating doses of anti-CTLA4 antibody, starting at 3 mg / kg and increasing to 6 mg / kg, 10 mg / kg, and 15 mg / kg after every 28 days, in the absence of intolerable toxicity or disease progression case for up to 12 consecutive cycles.

[0285] Preferably, the patient is given a premedication of antihistamine (H1 ) at least one and a half hours before anti-CTLA4 infusion. Premedic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and 10DI (MDX-010), in combination with an aromatase inhibitor, for treatment of breast cancer. More particularly, the invention relates to administration of an anti-CTLA4 antibody and exemestane for treatment of breast cancer.

Description

Background technique [0001] Each year, more than 180,000 women in the United States are diagnosed with breast cancer. If current breast cancer rates remain constant, each woman born today will have a one in 10 chance of developing breast cancer at an average age of about 60 to 65. [0002] Approximately two-thirds of postmenopausal breast cancer patients have estrogen-dependent disease, rendering them vulnerable to anti-estrogen therapy. Estrogen promotes the growth and proliferation of specific target cells such as mammary epithelial cells and estrogen-dependent breast cancer cells (Brueggemeier Amer J Therapeutics 8:333-344 (2001)). Thus, systemic adjuvant therapy, administered in addition to localized primary breast therapy (eg, breast-sparing surgery and radiation or mastectomy), focuses on drugs that block estrogen receptors on tumor cells. Such antihormonal drugs include tamoxifen (NOVALDEX D, SOLTAMOX, TAMOFEN), which inhibits the binding of estrogen to the estrogen r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395
CPCC07K16/2818A61K39/39541A61K2039/505C07K2317/21C07K2317/56A61P35/00A61P43/00A61K2300/00A61K39/395
Inventor J·戈麦斯-纳瓦罗
Owner PFIZER PROD INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap